Siberian Elm Leaf (Ulmus pumila)

Siberian elm leaf (Ulmus pumila) contains bioactive polyphenols, including catechins and tannins, alongside phytosterols that may exert antioxidant and anti-inflammatory effects through free radical scavenging. Research remains extremely limited, with most mechanistic evidence extrapolated from related elm species rather than direct human clinical trials on this leaf.

Origin & History

Siberian Elm Leaf (Ulmus pumila) is derived from a deciduous tree native to Central Asia, including eastern Siberia, Mongolia, and northern China. The research dossier provided contains no specific information about how Siberian Elm leaf is harvested or processed for supplemental use.

Historical & Cultural Context

The research dossier contains no information about traditional or historical uses of Siberian Elm leaf. Documentation of any traditional medicine applications would require access to ethnobotanical or traditional medicine databases not included in the provided research.

Health Benefits

• Limited published research available - the dossier contains no clinical studies on Ulmus pumila leaf specifically
• Related species (Ulmus laevis bark) showed anticancer activity in laboratory cell studies only
• No human clinical trials documented in the provided research
• No established health benefits verified through controlled studies
• Traditional use claims cannot be substantiated from the research provided

How It Works

Polyphenolic compounds in Ulmus pumila leaf, including catechin-type flavonoids and condensed tannins, are hypothesized to neutralize reactive oxygen species (ROS) and inhibit pro-inflammatory enzymes such as COX-2 and lipoxygenase. Phytosterols present in the leaf may competitively inhibit cholesterol absorption at intestinal brush border membranes. Related elm species bark extracts have demonstrated cytotoxic activity in vitro, potentially via apoptotic pathway induction, though the specific molecular targets in Ulmus pumila leaf have not been formally characterized.

Scientific Research

No clinical trials or meta-analyses for Siberian Elm Leaf (Ulmus pumila) were found in the research dossier. The only related study examined Ulmus laevis bark extract in laboratory cancer cell lines, finding triterpenes and phytosterols that inhibited cancer cell vitality while preserving normal cells - however, this represents a different species and only preliminary in vitro research.

Clinical Summary

No published human clinical trials specifically examining Ulmus pumila leaf have been identified in the peer-reviewed literature. Available evidence consists primarily of in vitro cell-line studies conducted on closely related species, such as Ulmus laevis bark, which showed anticancer activity against specific cancer cell lines under laboratory conditions only. Ethnobotanical use across Central Asia and traditional Chinese medicine provides anecdotal context but does not substitute for controlled clinical evidence. The overall evidence base is rated very low, and no quantified therapeutic outcomes, effective dosages, or validated biomarkers have been established for Ulmus pumila leaf specifically.

Nutritional Profile

Siberian Elm Leaf (Ulmus pumila) has limited published nutritional data specific to the leaf fraction. Based on available phytochemical analyses and related Ulmus species comparisons, the following constituents have been tentatively identified or inferred: Macronutrients: crude protein approximately 10–18% dry weight (young leaves); dietary fiber (cellulose, hemicellulose, pectin) approximately 15–25% dry weight; low lipid content (~2–5% dry weight). Micronutrients: calcium, potassium, magnesium, and iron have been reported in Ulmus species leaves at moderate levels (calcium ~1,000–2,000 mg/100g dry weight estimated), though species-specific quantification for U. pumila leaf is lacking. Bioactive compounds: flavonoids (quercetin, kaempferol, rutin) reported in Ulmus genus leaves at trace to moderate levels; tannins (catechins, condensed tannins) contributing astringent properties; phenolic acids (chlorogenic acid, caffeic acid derivatives); mucilaginous polysaccharides (notably in bark, presence in leaf less documented); triterpenoids and sterols (beta-sitosterol) tentatively identified. Bioavailability notes: Tannin content may inhibit protein and iron absorption when consumed in significant quantities. Flavonoid bioavailability is generally low without lipid co-ingestion or fermentation processing. All concentration values are approximate and extrapolated from related Ulmus species; no validated compositional analysis specific to U. pumila leaf has been confirmed in peer-reviewed literature.

Preparation & Dosage

No clinically studied dosage ranges are available from the research dossier. No standardized preparations or recommended doses have been established through clinical trials. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Cannot be determined without clinical research

Safety & Interactions

No formal human safety studies or toxicology trials exist for Ulmus pumila leaf supplements, making a comprehensive risk profile impossible to define at this time. Individuals with known hypersensitivity to elm species or the Ulmaceae plant family should avoid this ingredient due to potential cross-reactivity. Theoretical interactions with anticoagulant medications such as warfarin are plausible given tannin content, which may affect drug absorption and platelet aggregation, though this has not been clinically confirmed. Pregnant and breastfeeding women should avoid use entirely due to a complete absence of safety data in these populations.